Dramatic effect of ZD1839 ('Iressa') in a patient with advanced non-small-cell lung cancer and poor performance status

Keiichi Fujiwara, Katsuyuki Kiura, Hiroshi Ueoka, Masahiro Tabata, Shuji Hamasaki, Mitsune Tanimoto

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

We describe the case of a 52-year-old Japanese woman with advanced adenocarcinoma of the lung, in whom once-daily treatment with 250 mg ZD1839 ('Iressa') demonstrated a marked antitumour effect. She had initially achieved a partial response with cisplatin-based combination chemotherapy, but had subsequently progressed and had failed to respond to salvage chemotherapy. She had also received whole-brain irradiation for brain metastases. On admission, the patient was confined to bed due to dyspnoea and had rapidly progressing hypoxia secondary to lymphangitis carcinomatosa and a massive right pleural effusion. She was treated with oxygen supplementation and oral ZD1839, which, within a week, led to marked tumour regression and gradually improving dyspnoea. The main adverse event observed was a grade 2 rash. A month after starting ZD1839 treatment, the patient was discharged without the need for oxygen supplementation and had since returned to full-time work. This is a demonstration of ZD1839 producing a dramatic clinical response when administered to a patient with poor performance status who had received extensive prior treatment with cytotoxic agents.'Iressa' is a trademark of the AstraZeneca group of companies.

Original languageEnglish
Pages (from-to)73-76
Number of pages4
JournalLung Cancer
Volume40
Issue number1
DOIs
Publication statusPublished - Apr 1 2003

Fingerprint

Non-Small Cell Lung Carcinoma
Dyspnea
Lymphangitis
Oxygen
Patents
Cytotoxins
Brain
Pleural Effusion
Exanthema
Combination Drug Therapy
Cisplatin
gefitinib
Therapeutics
Neoplasm Metastasis
Drug Therapy
Neoplasms

Keywords

  • 'Iressa'
  • Non-small-cell lung cancer
  • Poor performance status
  • ZD1839

ASJC Scopus subject areas

  • Oncology

Cite this

Dramatic effect of ZD1839 ('Iressa') in a patient with advanced non-small-cell lung cancer and poor performance status. / Fujiwara, Keiichi; Kiura, Katsuyuki; Ueoka, Hiroshi; Tabata, Masahiro; Hamasaki, Shuji; Tanimoto, Mitsune.

In: Lung Cancer, Vol. 40, No. 1, 01.04.2003, p. 73-76.

Research output: Contribution to journalArticle

Fujiwara, Keiichi ; Kiura, Katsuyuki ; Ueoka, Hiroshi ; Tabata, Masahiro ; Hamasaki, Shuji ; Tanimoto, Mitsune. / Dramatic effect of ZD1839 ('Iressa') in a patient with advanced non-small-cell lung cancer and poor performance status. In: Lung Cancer. 2003 ; Vol. 40, No. 1. pp. 73-76.
@article{d8604a3e5dff48f88630b9663a63781f,
title = "Dramatic effect of ZD1839 ('Iressa') in a patient with advanced non-small-cell lung cancer and poor performance status",
abstract = "We describe the case of a 52-year-old Japanese woman with advanced adenocarcinoma of the lung, in whom once-daily treatment with 250 mg ZD1839 ('Iressa') demonstrated a marked antitumour effect. She had initially achieved a partial response with cisplatin-based combination chemotherapy, but had subsequently progressed and had failed to respond to salvage chemotherapy. She had also received whole-brain irradiation for brain metastases. On admission, the patient was confined to bed due to dyspnoea and had rapidly progressing hypoxia secondary to lymphangitis carcinomatosa and a massive right pleural effusion. She was treated with oxygen supplementation and oral ZD1839, which, within a week, led to marked tumour regression and gradually improving dyspnoea. The main adverse event observed was a grade 2 rash. A month after starting ZD1839 treatment, the patient was discharged without the need for oxygen supplementation and had since returned to full-time work. This is a demonstration of ZD1839 producing a dramatic clinical response when administered to a patient with poor performance status who had received extensive prior treatment with cytotoxic agents.'Iressa' is a trademark of the AstraZeneca group of companies.",
keywords = "'Iressa', Non-small-cell lung cancer, Poor performance status, ZD1839",
author = "Keiichi Fujiwara and Katsuyuki Kiura and Hiroshi Ueoka and Masahiro Tabata and Shuji Hamasaki and Mitsune Tanimoto",
year = "2003",
month = "4",
day = "1",
doi = "10.1016/S0169-5002(03)00028-X",
language = "English",
volume = "40",
pages = "73--76",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Dramatic effect of ZD1839 ('Iressa') in a patient with advanced non-small-cell lung cancer and poor performance status

AU - Fujiwara, Keiichi

AU - Kiura, Katsuyuki

AU - Ueoka, Hiroshi

AU - Tabata, Masahiro

AU - Hamasaki, Shuji

AU - Tanimoto, Mitsune

PY - 2003/4/1

Y1 - 2003/4/1

N2 - We describe the case of a 52-year-old Japanese woman with advanced adenocarcinoma of the lung, in whom once-daily treatment with 250 mg ZD1839 ('Iressa') demonstrated a marked antitumour effect. She had initially achieved a partial response with cisplatin-based combination chemotherapy, but had subsequently progressed and had failed to respond to salvage chemotherapy. She had also received whole-brain irradiation for brain metastases. On admission, the patient was confined to bed due to dyspnoea and had rapidly progressing hypoxia secondary to lymphangitis carcinomatosa and a massive right pleural effusion. She was treated with oxygen supplementation and oral ZD1839, which, within a week, led to marked tumour regression and gradually improving dyspnoea. The main adverse event observed was a grade 2 rash. A month after starting ZD1839 treatment, the patient was discharged without the need for oxygen supplementation and had since returned to full-time work. This is a demonstration of ZD1839 producing a dramatic clinical response when administered to a patient with poor performance status who had received extensive prior treatment with cytotoxic agents.'Iressa' is a trademark of the AstraZeneca group of companies.

AB - We describe the case of a 52-year-old Japanese woman with advanced adenocarcinoma of the lung, in whom once-daily treatment with 250 mg ZD1839 ('Iressa') demonstrated a marked antitumour effect. She had initially achieved a partial response with cisplatin-based combination chemotherapy, but had subsequently progressed and had failed to respond to salvage chemotherapy. She had also received whole-brain irradiation for brain metastases. On admission, the patient was confined to bed due to dyspnoea and had rapidly progressing hypoxia secondary to lymphangitis carcinomatosa and a massive right pleural effusion. She was treated with oxygen supplementation and oral ZD1839, which, within a week, led to marked tumour regression and gradually improving dyspnoea. The main adverse event observed was a grade 2 rash. A month after starting ZD1839 treatment, the patient was discharged without the need for oxygen supplementation and had since returned to full-time work. This is a demonstration of ZD1839 producing a dramatic clinical response when administered to a patient with poor performance status who had received extensive prior treatment with cytotoxic agents.'Iressa' is a trademark of the AstraZeneca group of companies.

KW - 'Iressa'

KW - Non-small-cell lung cancer

KW - Poor performance status

KW - ZD1839

UR - http://www.scopus.com/inward/record.url?scp=0037378457&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037378457&partnerID=8YFLogxK

U2 - 10.1016/S0169-5002(03)00028-X

DO - 10.1016/S0169-5002(03)00028-X

M3 - Article

VL - 40

SP - 73

EP - 76

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - 1

ER -